Looking ahead, Wall Street forecasts adjusted EPS of $23.21 for fiscal 2025, representing a 78.7% increase from $12.99 in ...

China These authors contributed equally to this work. Correspondence to: Dr. Xi Cao, Beijing Diabetes Institute, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, No.

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist orforglipron reached the main goal in a Phase 3 trial for adults with ...

(CNN) — Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after ...

New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Drugmaker Eli Lilly said that in Phase 3 ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease ...